We’re thrilled to announce that our Managing Director and Chief Scientist, Chris Foley, PhD, is representing bioXcelerate AI at this year’s American Society of Human Genetics (ASHG) Annual Meeting. Held in Denver, Colorado, the ASHG 2024 conference brings together thought leaders, researchers, and innovators from around the globe to explore the latest advancements in human… Continue reading bioXcelerate AI at ASHG 2024: Presenting Genetic Research with ImpMap and SwitchStep
Author: bioxcelerate
Building Data Assets in Drug Discovery
Large population-based cohort studies like UK Biobank are crucial for drug discovery, providing the statistical power needed to identify small effects that would otherwise go unnoticed. Data assets can be generated in-house or accessed from external sources, each approach having its own advantages and challenges. Pharmaceutical research demands structured, quality data, with drug development being… Continue reading Building Data Assets in Drug Discovery
Methods in Applied Genetic Epidemiology 2022
View the Full Frontiers Editorial Genetic epidemiology holds immense potential to revolutionise our understanding of human disease aetiology, progression, and prevention. In a recently published editorial in Frontiers, our Managing Director and Chief Scientist, Chris Foley PhD, and Director of Health Data Science, Zhana Kuncheva PhD, discuss the critical developments and challenges in the field.… Continue reading Methods in Applied Genetic Epidemiology 2022
Unleashing the power of genomics with population scale proteomics
At the recent Nordic Conference on Future Health, Chris Foley PhD, our Managing Director and Chief Scientist, was a distinguished guest speaker at Olink’s workshop titled Navigating the UKB Plasma Proteomics Data to Explore Protein Variability, Disease Risk Scores, and Proteogenomic Associations. This workshop focused on the UK Biobank Pharma Proteomics Project (UKB-PPP), which stands… Continue reading Unleashing the power of genomics with population scale proteomics
Dr Afyouni Discusses AI in Healthcare at the RSSI
We are delighted to share that Dr Soroosh Afyouni, PhD, Head of Health Data Science at bioXcelerate AI, was a panellist at the Royal Statistical Society (RSS) International Conference 2024, to discuss AI in healthcare. The RSS Conference is the UK’s premier event for statistics and data science, bringing together over 600 professionals from more… Continue reading Dr Afyouni Discusses AI in Healthcare at the RSSI
Dr Zhana Kuncheva on the AI Revolution in Healthcare
We are excited to announce that Zhana Kuncheva, our Director of Health Data Science, recently published an insightful article in Pharma IQ titled “Unlocking Health Data’s Potential: The AI Revolution in Healthcare.” This article explores how artificial intelligence (AI) is transforming healthcare by unlocking the value hidden in vast data reserves, with a particular focus… Continue reading Dr Zhana Kuncheva on the AI Revolution in Healthcare
Breakthrough Research Spotlighted in Pharma IQ
Our Managing Director & Chief Scientist, Dr Chris Foley, and Dr Riccardo Marioni, Chair of Molecular Epidemiology of Ageing at the University of Edinburgh, were recently interviewed by Pharma IQ about their groundbreaking research. This study, a collaboration between bioXcelerate AI, Biogen, and the University of Edinburgh, marks a significant advancement in predictive health. In… Continue reading Breakthrough Research Spotlighted in Pharma IQ
Systematic discovery of gene-environment interactions underlying the human plasma proteome in UK Biobank
View the full research paper on Nature Communications Objectives: This study aimed to explore how gene-environment interactions (GEIs) affect protein levels in the human body, specifically within the plasma proteome. The focus was on identifying variance quantitative trait loci (vQTLs) that signal these interactions, and understanding how genetic and environmental factors together influence protein expression.… Continue reading Systematic discovery of gene-environment interactions underlying the human plasma proteome in UK Biobank
New Advances in Disease Risk Prediction
Objectives: The primary goal was to identify genetic variants linked to Alzheimer’s disease (AD) using advanced genomic techniques. The study aimed to enhance understanding of the genetic underpinnings of AD by employing sophisticated methods to analyse large-scale genomic data. Key objectives included pinpointing novel genetic variants associated with AD, elucidating their functional roles, and exploring… Continue reading New Advances in Disease Risk Prediction
isGWAS Showcased at ESHG2024 in Berlin
We are delighted to announce that bioXcelerate AI’s innovative work was showcased at the prestigious European Society of Human Genetics (ESHG) Conference in Berlin. The ESHG event is a key platform for geneticists from Europe and around the world to share breakthroughs and advancements in human genetics research. At the conference, Dr. Heiko Runz, a… Continue reading isGWAS Showcased at ESHG2024 in Berlin